Fomivirsen
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pregnancy category |
|
| Routes of administration | Intravitreal injection |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C204H263N63O114P20S20 |
| Molar mass | 6682.35 g·mol−1 |
  (what is this?) (verify) | |
Fomivirsen (brand name Vitravene) is an
AIDS. It was administered via intraocular injection.[1]
It was discovered at the NIH and was licensed and initially developed by Isis Pharmaceuticals, which subsequently licensed it to Novartis.[2] It was licensed by the FDA for CMV in Aug 1998, and was the first antisense drug that was approved.[3]
Novartis withdrew the marketing authorization in the EU in 2002HAART dramatically reduced the number of cases of CMV.[2]
It is an
antisense oligonucleotide -- a synthetic 21 member oligonucleotide with phosphorothioate linkages (which are resistant to degradation by nucleases
) and has the sequence:
- 5'-GCG TTT GCT CTT CTT CTT GCG-3'
References
- ISBN 978-0-07-178923-3.
- ^ PMID 25830190. Archived from the originalon 2017-09-29. Retrieved 2017-01-02.
- ^ Jiang K (February 19, 2013). "Biotech comes to its 'antisenses' after hard-won drug approval : Spoonful of Medicine". Nature Medicine: Spoonful of Medicine Blog.
- ^ "Public Statement on Vitravene (fomiversen): Withdrawal of the Marketing Authorization in the European Union" (PDF). EMA. August 6, 2002. Archived from the original (PDF) on May 23, 2018. Retrieved January 2, 2017.
- ^ "Initiating Coverage: Rexahn Pharmaceuticals (RNN)" (PDF). LifeSci Capital. May 23, 2016.
- PMID 9559825.
- S2CID 6983051.
Further reading
- Grillone LR, Lanz R (April 2001). "Fomivirsen". Drugs of Today. 37 (4): 245–255. PMID 12768225.
- Geary RS, Henry SP, Grillone LR (2002). "Fomivirsen: clinical pharmacology and potential drug interactions". Clinical Pharmacokinetics. 41 (4): 255–260. S2CID 22134649.
- Boyer DS, Cowen SJ, Danis RP, Diamond JG, Fish RH, Goldstein DA, et al. (Vitravene Study Group) (April 2002). "Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS". American Journal of Ophthalmology. 133 (4): 475–483. PMID 11931781.
- Roehr B (October 1998). "Fomivirsen approved for CMV retinitis". Journal of the International Association of Physicians in AIDS Care. 4 (10): 14–16. PMID 11365956.